VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 02, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098.
